121 related articles for article (PubMed ID: 9472552)
1. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
[TBL] [Abstract][Full Text] [Related]
2. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
[TBL] [Abstract][Full Text] [Related]
4. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
Gokhale PC; McRae D; Monia BP; Bagg A; Rahman A; Dritschilo A; Kasid U
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):191-201. PubMed ID: 10355825
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
Dritschilo A; Huang CH; Rudin CM; Marshall J; Collins B; Dul JL; Zhang C; Kumar D; Gokhale PC; Ahmad A; Ahmad I; Sherman JW; Kasid UN
Clin Cancer Res; 2006 Feb; 12(4):1251-9. PubMed ID: 16489081
[TBL] [Abstract][Full Text] [Related]
6. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
Soldatenkov VA; Dritschilo A; Wang FH; Olah Z; Anderson WB; Kasid U
Cancer J Sci Am; 1997; 3(1):13-20. PubMed ID: 9072302
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
9. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
McPhillips F; Mullen P; Monia BP; Ritchie AA; Dorr FA; Smyth JF; Langdon SP
Br J Cancer; 2001 Nov; 85(11):1753-8. PubMed ID: 11742498
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract][Full Text] [Related]
12. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
13. A comparison of in vivo gene delivery methods for antisense therapy in ligament healing.
Nakamura N; Timmermann SA; Hart DA; Kaneda Y; Shrive NG; Shino K; Ochi T; Frank CB
Gene Ther; 1998 Nov; 5(11):1455-61. PubMed ID: 9930298
[TBL] [Abstract][Full Text] [Related]
14. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
15. RAF antisense oligonucleotide as a tumor radiosensitizer.
Kasid U; Dritschilo A
Oncogene; 2003 Sep; 22(37):5876-84. PubMed ID: 12947394
[TBL] [Abstract][Full Text] [Related]
16. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Khatib AM; Fallavollita L; Wancewicz EV; Monia BP; Brodt P
Cancer Res; 2002 Oct; 62(19):5393-8. PubMed ID: 12359742
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effects of C-erbB-2 and C-raf-1 gene combined with antisense oligodeoxynucleotide on the human ovarian carcinoma transplanted subcutaneously in nude mice].
Wu YZ; Ren QL; Li SL
Ai Zheng; 2003 Aug; 22(8):836-9. PubMed ID: 12917030
[TBL] [Abstract][Full Text] [Related]
19. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
20. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy.
Thomas SM; Zeng Q; Dyer KF; Suscovich TJ; Kanter PM; Whalen JD; Watkins SF; Grandis JR
Cancer Gene Ther; 2003 Jul; 10(7):518-28. PubMed ID: 12833132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
